Webcast positive OCEAN topline results
May 25, 2021
Oncopeptides presented positive topline results from the phase 3 OCEAN and hosted a webcast Tuesday May 25, 2021.
Post ASH 2020 – webcast & presentation
December 9, 2020
Oncopeptides hosted a webcast on Wednesday, December 9th at 14:00 (CET) to provide an update regarding data presented at the ASH annual meeting. The webcast was recorded and hosted by CEO Marty J Duvall, CSO Jakob Lindberg and CMO Klaas Bakker.
ANCHOR presentation at ASH 2020
December 6, 2020
Oncopeptides presented new data from phase 2 ANCHOR combination study in multiple myeloma the 62nd American Society of Hematology virtual annual meeting ASH, December 6, 2020.
The presentation to the webcast – top-line data HORIZON
June 16, 2020
Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients. On June 16 at 10:00 (CET), CEO Jakob Lindberg comments on the top-line results.
EHA 2020 – posters
June 15, 2020
Oncopeptides reports positive results from full data set of Phase 2 HORIZON trial in triple-class refractory multiple myeloma patients as well as several other posters during EHA.
Presentation webcast HORIZON Topline results
March 26, 2020
Oncopeptides hosted a webcast to present the HORIZON study data and provided a general clinical update March 26, 2020.
Presentation – Webcast melflufen’s mechanism of action
January 24, 2020
Oncopeptides hosted a webcast on Monday, January 27th 2020 were CEO Jakob Lindberg presented and explained melflufen’s mechanism of action. Investors, analysts and the media were invited to the webcast.
Post ASH Webcast 2019
December 10, 2019
Oncopeptides CEO Jakob Lindberg summarized our data and presentations post ASH in a webcast December 10, 2019.
December 7, 2019
Poster presentations held at ASH 2019.
ASH Abstracts 2019
November 6, 2019
Oncopeptides to highlight data from melflufen clinical program in multiple myeloma and AL Amyloidosis in six presentations at ASH Annual Meeting 2019.
Lymphoma & Myeloma Congress 2019
October 24, 2019
In New York, USA, Oncopeptides presented three posters at the Lymphoma & Myeloma Congress 2019. See the posters below.
European Society for Medical Oncology 2019 (ESMO) September 27th, 2019
September 27, 2019
Oncopeptides presented one poster at the ESMO meeting in Barcelona, Spain. See the Poster below.
IMW 2019 oral presentation
September 15, 2019
Oncopeptides presented new interim data in RRMM Patients with Extramedullary Disease (EMD) from the Pivotal Phase 2 Horizon-study at the 17th International Myeloma Workshop (IMW) meeting in Boston, Massachusetts, USA. The data focused on patients with extramedullary disease (EMD) and was presented in an oral presentation by Professor Paul G. Richardson.
IMW 2019 Posters
September 14, 2019
Oncopeptides presented two poster at the 17th International Myeloma Workshop (IMW) meeting in Boston, Massachusetts, USA. See the Posters below.
Society of Hematologic Oncology (SOHO) 2019
September 11, 2019
At the Society of Hematologic Oncology (SOHO) 2019 Annual Meeting in Houston, TX, USA, clinical trial data from two of our trials HORIZON and ANCHOR were presented. In an oral presentation, data from the pivotal Phase 2 HORIZON clinical trial were presented as part of the meeting’s multiple myeloma session. Additionally, two posters focused on the ANCHOR and HORIZON clinical trials evaluating melflufen in RRMM were displayed at the meeting.
EHA 2019 – presentations and articles
June 24, 2019
During 2019 European Hematology Association (EHA) Congress, Oncopeptides presented updated interim data from the ongoing phase 1/2 ANCHOR study, data from its phase 1/2 O-12-M1 study and updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial. These presentations as well as publications in the media are presented below. The ANCHOR and O-12-M1 Posters, the oral presentation of HORIZON by Professor Paul G. Richardson and several external links and videos regarding publications in the media.
ASCO 2019 – presentations and articles
June 21, 2019
During 2019 ASCO General Meeting (American Society of Clinical Oncology), Oncopeptides presented new data from phase 1/2 O-12-M1 trial evaluating melflufen in RRMM. These data was presented by Professor Paul G. Richardson.
Post EHA – webcast regarding data update
June 17, 2019
Oncopeptides hosted a webcast on Monday, 17 June to review and update presentations from European Hematology Association (EHA) meeting. It was presented by CEO Jakob Lindberg and members of the Oncopeptides management team.
EHA 2019 – Oral Presentation
June 16, 2019
Professor Paul G. Richardson held an oral presentation of the study HORIZON at EHA 2019 on 16 June.
EHA 2019 – posters
June 14, 2019
Poster presentations at EHA June 14th, 2019.
2019 ASCO Annual Meeting – poster
June 3, 2019
New data from Oncopeptides phase 1/2 O-12-M1 trial evaluating melflufen in RRMM presented at 2019 ASCO annual meeting by Professor Paul G. Richardson.
EHA Abstracts 2019
May 16, 2019
Upcoming presentations at EHA - four abstracts from Oncopeptides
ASCO Abstract 2019
May 15, 2019
Oncopeptides has a poster presentation of data from its Phase 1/2 O-12-M1 study at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4 in Chicago. The study evaluates melflufen in the treatment of relapsed/refractory multiple myeloma (RRMM), Melflufen is a lipophilic peptide-conjugated alkylator belonging to the novel class of Peptidase Enhanced Cytotoxics (PEnC).
AACR 2019 – Posters
April 3, 2019
At the AACR (American Association for Cancer Research) Annual Meeting 2019 Oncopeptides presented two Posters for the studies ANCHOR and HORIZON.
ASH 2018 – presentations and articles
December 10, 2018
During the American Hematology Meeting (ASH), Oncopeptides presented data from two ongoing studies, ANCHOR and HORIZON.
59th ASH Annual Meeting & Exposition – Posters
December 9, 2018
Horizon Poster (9 Dec 2017) and O-12-M1 Poster (10 Dec 2017).
Professor Paul G. Richardson presentation at ASH 2018 – The HORIZON study
December 3, 2018
Professor Paul G. Richardson presentation at ASH 2018 – The HORIZON study.
60th ASH Annual Meeting & Exposition – Poster ANCHOR
December 1, 2018
ANCHOR poster. Oncopeptides presents the first interim data with melflufen (Ygalo®) from the ongoing phase I/II study ANCHOR at the 60th ASH meeting in San Diego, California, USA (December 1, 2018).
ASH Abstracs 2018
November 1, 2018
Oncopeptides to present updated data from the two ongoing trials ANCHOR and HORIZON in patients with RRMM at ASH in December 2018. The abstract data cut for ANCHOR was July 18th and for HORIZON, May 10th. Further data supporting melflufen’s activity has been generated since the abstract data cut and will be presented at ASH.
Presentation at 23rd Congress of The European Hematology Association (EHA)
June 15, 2018
The updated phase II-data show a clinical data set with an Overall Response Rate (ORR) of 32.1% and a Clinical Benefit Rate (CBR) of 39.3% with Ygalo® in relapsed/refractory multiple myeloma patients refractory to pomalidomide and/or daratumumab after failing on immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs).
ASH summary Webcast
December 13, 2017
Oncopeptides had a press conference on December 13, 2018. View the recorded webcast.
American Society of Hematology (ASH) – Abstract
November 1, 2017